News
HCM
19.90
-0.95%
-0.19
Weekly Report: what happened at HCM last week (0513-0517)?
Weekly Report · 1d ago
HUTCHMED’s Breakthroughs in Hematology Spotlighted
TipRanks · 4d ago
HUTCHMED ANNOUNCES RETIREMENT OF CHAIRMAN, APPOINTMENT OF NEW CHAIRMAN AND CHANGE OF MEMBERS OF BOARD COMMITTEES
Reuters · 4d ago
HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
Barchart · 4d ago
Reported Earlier, HUTCHMED To Present Sovleplenib Phase III ESLIM-01 Study And Hematological Malignancy Programs Data At The Upcoming EHA2024 Congress
Topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib will be presented at the European Hematology Association Hybrid Congress in 2024. New data related to novel investigational hematological malignancy therapies will also be presented.
Benzinga · 5d ago
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
Results from the ESLIM-01 Phase III study of sovleplenib will be presented at the upcoming European Hematology Association Hybrid Congress in June 2024. New and updated data related to novel investigational hematological malignancy therapies will also be presented.
Barchart · 5d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: HUTCHMED (HCM) and PAVmed (PAVM)
TipRanks · 6d ago
HUTCHMED Launches Innovative Cancer Treatment Trial
TipRanks · 05/14 12:02
Reported Earlier, HUTCHMED Initiates The RAPHAEL Registrational Phase III Trial Of HMPL-306 For Patients With IDH1- And/Or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia In China
HMPL-306 is a novel dual-inhibitor of IDH1 and IDH2 enzymes. Mutations of the enzymes have been implicated as drivers of certain hematological malignancies, gliomas and solid tumors. Targeting both mutations may provide therapeutic benefits in cancer patients.
Benzinga · 05/14 07:40
Reported Earlier, HUTCHMED Initiates Phase II/III Trial Of The Combination Of Surufatinib And Camrelizumab For Treatment-Naïve Pancreatic Ductal Adenocarcinoma In Collaboration With Hengrui
Benzinga · 05/14 07:38
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
Barchart · 05/13 19:00
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
The first patient received their first dose of HMPL-306 on May 11, 2024. The first patient will be treated for acute myeloid leukemia in China. HUTCHMED has initiated a registrational Phase III clinical trial of the drug in patients with relapsed or refractory leukemia.
Barchart · 05/13 19:00
Weekly Report: what happened at HCM last week (0506-0510)?
Weekly Report · 05/13 09:28
Hutchmed Shareholders Approve All AGM Resolutions
TipRanks · 05/10 13:27
Spectrum Brands Posts Upbeat Results, Joins AerSale, Sinclair, ICU Medical And Other Big Stocks Moving Higher On Thursday
Spectrum Brands Holdings, Inc. Shares surged 12.4% to $95.00 on Thursday. The company posted upbeat earnings of $1.62 per share. The Dow Jones gained around 100 points in today's session. Shares of Sezzle Inc. Rose 69.9% following upbeat quarterly results.
Benzinga · 05/09 14:25
HUTCHMED Welcomes New Board Member Expertise
TipRanks · 05/08 11:31
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
Dr Renu Bhatia is appointed as an Independent Non-executive Director and a member of Technical Committee of the Company with effect from May 13, 2024. HUTCHMED (China) Limited announces Dr Renu's appointment to the Board of Directors of the company.
Barchart · 05/08 03:30
Weekly Report: what happened at HCM last week (0429-0503)?
Weekly Report · 05/06 09:30
HUTCHMED Nears EU Approval for Cancer Drug
TipRanks · 04/29 10:57
Weekly Report: what happened at HCM last week (0422-0426)?
Weekly Report · 04/29 09:32
More
Webull provides a variety of real-time HCM stock news. You can receive the latest news about Hutchmed (China) Limited through multiple platforms. This information may help you make smarter investment decisions.
About HCM
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.